Edible vs. Vaporized Cannabis: Why Timing Changes the Evidence

Cannabis is not one exposure with one predictable timeline.

An edible must pass through the gastrointestinal tract and first-pass metabolism. Vaporized THC enters through the lungs and reaches the blood rapidly. Those routes can produce different relationships among dose, blood concentration, subjective effects, and performance.

A 2021 controlled study in the Journal of Psychopharmacology compared oral and vaporized THC in the same group of adults who used cannabis infrequently. Its results expose a basic weakness in many cannabis cases: a blood number and a roadside observation are often treated as if they measure the same thing at the same time. They do not.

What the researchers actually tested

Twenty adults, ten men and ten women, completed six double-blind outpatient sessions. They consumed brownies containing 0, 10, or 25 milligrams of THC and, in separate sessions, inhaled vaporized cannabis containing 0, 5, or 20 milligrams of THC.

The investigators measured blood THC, subjective effects, computerized cognitive and psychomotor performance, a mobile impairment application called DRUID, and several common field sobriety tasks. Because the participants used cannabis infrequently, the design reduced, but did not eliminate, the complication of tolerance associated with frequent use.

The high oral and vaporized doses impaired cognitive and psychomotor performance relative to placebo. The low doses produced subjective effects but did not significantly impair the measured cognitive and psychomotor outcomes relative to placebo. That distinction matters. Feeling an effect, showing a statistical group difference, and proving that one person could not drive safely are not interchangeable conclusions.

Oral cannabis produced delayed effects

The onset of effects after the edible was substantially delayed compared with vaporized cannabis. The broader literature discussed in the study describes edible effects beginning approximately 30 to 45 minutes after ingestion, peaking later, and in some circumstances persisting for hours.

This delay creates a timing problem in forensic reconstruction. A person may consume an edible well before a law-enforcement encounter but experience changing effects during the interval between driving, observation, arrest, testing, and blood collection. The same dose can produce different concentration and effect patterns depending on formulation, food, absorption, metabolism, and individual response.

A blood sample collected later does not rewind those processes. It measures the specimen at the collection time. Any opinion about an earlier time requires assumptions that must be stated and supported.

Vaporized cannabis produced rapid blood peaks and rapid decline

After inhalation, blood THC rose quickly and then declined rapidly. The researchers reported that blood THC concentrations typically returned toward baseline before the measured pharmacodynamic effects had ended.

That separation between concentration and effect is crucial. A low later concentration does not prove there were no earlier effects. A higher concentration shortly after inhalation does not establish the degree of behavioral impairment in a particular person. Distribution from blood into tissues, prior use, tolerance, the delay to collection, and the measurement method all complicate the relationship.

This is the central problem addressed in Concentration Is Not Impairment: THC Blood Levels in California Driving Cases. The number is evidence. It is not a self-interpreting verdict.

Field sobriety tests showed little sensitivity to cannabis effects

The field sobriety tasks used in the study showed little sensitivity to cannabis-induced impairment. The researchers did not find significant differences among dosing conditions in the number of participants classified as impaired by the specified clue threshold on those tasks.

That result should not be inflated into a claim that field observations never matter. It shows that the tested field sobriety tasks did not reliably separate the controlled cannabis conditions in this sample. The tasks were developed principally in an alcohol context, and cannabis can affect people differently from alcohol.

The limitations of calling these exercises direct tests of driving are examined in What the Field Sobriety Tests Actually Measure.

The DRUID application was more sensitive in this study

The DRUID application detected significant differences between placebo and active doses within both routes and was the most sensitive performance measure evaluated in the study. That is a study-specific finding, not universal validation of a roadside device.

The authors disclosed that one coauthor created the DRUID application and was an officer and stockholder of the company associated with it. The paper also called for more research and replication in larger and more diverse samples.

Sensitivity alone is not enough for a forensic decision tool. A test must also establish specificity, repeatability, decision thresholds, error rates, resistance to practice effects, performance across age and medical conditions, and the consequences of false-positive and false-negative classifications.

A THC concentration is not a stopwatch

The route-specific findings make backward timing especially difficult. Oral THC can produce low blood concentrations alongside delayed or continuing effects. Vaporized THC can produce a high early concentration followed by a rapid decline while measurable effects persist.

Without reliable information about route, dose, product, use time, collection time, and prior-use pattern, the same measured concentration can fit more than one history. A concentration cannot, by itself, determine:

• The precise time of consumption
• Whether the product was eaten, smoked, or vaporized
• The concentration at an earlier driving time
• The person’s degree of tolerance
• Which observed behavior was caused by THC
• Whether another drug, fatigue, anxiety, injury, or medical condition contributed
• Whether the person was unable to operate a vehicle safely

The scientific question is not whether THC was present. It is what the complete evidence supports about timing, effect, and causation.

What should be obtained in a cannabis-impairment review

A case-specific review should obtain:

1. The exact driving, stop, observation, arrest, and blood-collection times.
2. The reported route, product, dose, potency, formulation, and time of use.
3. The person’s prior-use pattern and evidence relevant to tolerance.
4. Body-camera, dash-camera, dispatch, driving, and witness evidence.
5. The complete field-test instructions, demonstrations, surface conditions, footwear, lighting, and scoring.
6. Medical, vision, balance, neurological, medication, sleep, and injury information relevant to performance.
7. The laboratory method, validation, chromatograms, calibrators, controls, uncertainty, and reporting limits.
8. Whole-blood THC and metabolite results, with the specimen matrix and collection time stated correctly.
9. Evidence of alcohol or other drugs that may add to, oppose, or complicate the observed effects.
10. Every assumption used to connect the later blood result to the earlier driving time.

When alcohol is also present, the evidentiary problem changes again. See Cannabis and Alcohol Together: Impairment and Field Signs.

Important limits of the study

This was a controlled experiment involving 20 adults who used cannabis infrequently. Controlled dosing increases internal reliability, but it does not reproduce every roadside condition or every cannabis user.

The study tested specific oral and vaporized doses, selected performance tasks, and a limited observation window. Larger and more diverse samples are needed. Frequent users may respond differently because of tolerance. Real-world products also differ in potency, cannabinoid composition, formulation, and delivery efficiency.

The study supports route-specific timing and method limitations. It does not establish a universal safe waiting period, a per-se blood threshold, or an infallible behavioral test.

The bottom line

Oral and vaporized cannabis do not produce the same concentration-effect timeline. In this controlled study, edible effects were delayed, while blood THC after vaporization declined toward baseline before all measured effects had subsided. Common field sobriety tasks showed little sensitivity to the cannabis conditions tested.

That evidence does not make the blood test irrelevant or every observation meaningless. It means the interpretation must follow the route, timing, complete laboratory record, behavior, and alternative explanations. A THC number is one part of the evidence. It is not impairment by itself.

Primary source

Spindle TR, Martin EL, Grabenauer M, Woodward T, Milburn MA, Vandrey R. Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis. Journal of Psychopharmacology. 2021;35(7):786-803. PubMed record. PubMed Central full-text record. SAGE Journals record. doi:10.1177/02698811211021583.

Editorial note: This article paraphrases the published research. Do not upload or reproduce the source PDF, publisher layout, tables, or figures.